Therefore, in addition to the protective role of IFN-β itself for the AVN, our results suggest that SIRT1 or IL-6 also might be used as therapeutic targets of AVN for the development of pharmacological drug to protect against AVN. The gene discussed is IL6; the disease is avascular necrosis.